News and Events

Here is a summary of all Chemspace news and highlights for February, in case you missed it.

We are excited to announce that Olga Tarkhanova, PhD and Uliana Matviienko will be participating in the ACS Spring Meeting 2025 in San Diego from March 23-27, presenting two talks in the main technical program.

Join us on March 13th for an exclusive webinar with Olga Tarkhanova, PhD, and David Cosgrove, PhD. What’s in it for you?

Chemspace, Enamine, and PharmAI GmbH Discovery (PAID) start a transformative collaboration to accelerate the advancement of theranostics through AI-driven drug discovery with an emphasis on cancer diagnosis and therapy.

Three years of pain. Three years of strength. Three years of fighting for our future.

We are thrilled to be a sponsor of Bio-IT World Conference & Expo 2025! Plus, as a sponsor, we have an exclusive promo code for $200 OFF your registration!

Great news! Freedom Space 4.0, encompassing 142 billion synthetically accessible molecules, is now searchable through Alipheron's advanced tools: Hyperspace and Pharos-3D.

Join us at the Chemspace Webinar: A Journey Into the Freedom Space of 142 Billion Molecules!

Freedom Space 4.0 is now fully accessible within BioSolveIT’s computational tools! 

Exciting news! You can now easily search the updated 5B version of Freedom Space 4.0 with the new Freedom Space category!

Here is a summary of all Chemspace news and highlights for January, in case you missed it.

CRENESSITY™ (crinecerfont), the oral antagonist of the corticotropin-releasing factor type 1 receptor (CRF1), was approved by the FDA in December 2024 as the first new therapy in 70 years for classic congenital adrenal hyperplasia (CAH)  and represents a significant breakthrough in managing this rare genetic condition.

More molecules, more freedom, more discovery - meet the NEW Freedom Space 4.0! 

May the Year of the Dragon fill your days with harmony, and success. Let it inspire new achievements and meaningful connections throughout the year!

We are thrilled to share our conference lineup for February through June! Chemspace is gearing up for an incredible start to 2025. Here’s where you can find us.

We at Chemspace are thrilled to join EFPIA and its “Partners in Research” initiative!  

In 2024, Microtubule-Associated Protein Tau (MAPT) has been a major focus in neurodegeneration research. To support advancements in this field, we have curated a set of Chemspace Biologics.

By using advanced computing solutions and our collaboration with Fovus, we optimize complex simulations without compromising on speed or accuracy. The result? More reliable predictions and better-targeted compound selections.

We are excited to announce the launch of our brand-new Biologics webpage on Chemspace’s website! 

Happy New Year! Now, let’s take a look back at some of the key milestones we achieved together in 2024.

2024 brought its share of challenges, but thanks to your support and trust, it was also a year of growth, learning, and teamwork.

TRPV1, a key target for new analgesics, mediates pain signaling, neuroinflammation, and more. Explore its role with our curated Chemspace Biologics set!

Discover the potential of the 2,7-diazaspiro[3.5]nonane core! Inspired by revumenib, we offer building blocks featuring this unique fragment for your drug discovery needs.

This year was amazing for our Drug Discovery team! We took on big challenges, hit exciting milestones, and made great progress. Let’s look back at what we achieved!

Last week, Enamine and Elsevier announced a collaboration to integrate 43 million MADE analog compounds into Reaxys, enhancing resources for chemical discovery!